Bausch Health Companies Inc. Weighted Average Number of Shares Outstanding, Basic and Diluted
Bausch Health Companies Inc. (BHC) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 355.00 million shares for the 12-month period ending 2020-12-31, per its 8-K filed 2021-05-04.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-05-04
- Bausch Health Companies Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 355.30M shares, a 0.91% increase year-over-year.
- Bausch Health Companies Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-03-31 was 353.40M shares, a 0.60% increase year-over-year.
- Bausch Health Companies Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2019-12-31 was 352.70M shares, a 0.23% increase year-over-year.
- Bausch Health Companies Inc. weighted average number of shares outstanding, basic and diluted for the quarter ending 2019-09-30 was 352.40M shares, a 0.26% increase year-over-year.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|---|
| 2020-12-31 | 355.00M shares 8-K · filed 2021-05-04 | ||||
| 2020-06-30 | 355.30M shares 10-Q · filed 2020-08-06 | 354.30M shares 10-Q · filed 2020-08-06 | 353.80M shares derived: average of 3 quarters · filed 2021-05-04 | 353.45M shares derived: average of 4 quarters · filed 2021-05-04 | |
| 2020-03-31 | 353.40M shares 10-Q · filed 2020-05-07 | 353.05M shares derived: average of 2 quarters · filed 2021-05-04 | 352.83M shares derived: average of 3 quarters · filed 2021-05-04 | 352.65M shares derived: average of 4 quarters · filed 2021-05-04 | |
| 2019-12-31 | 352.70M shares derived: 8-K 12 month − 10-Q 9 month · filed 2021-05-04 | 352.55M shares derived: average of 2 quarters · filed 2021-05-04 | 352.40M shares derived: average of 3 quarters · filed 2021-05-04 | 352.10M shares 8-K · filed 2021-05-04 | |
| 2019-09-30 | 352.40M shares 10-Q · filed 2019-11-04 | 352.25M shares derived: average of 2 quarters · filed 2020-08-06 | 351.90M shares 10-Q · filed 2019-11-04 | 351.93M shares derived: average of 4 quarters · filed 2021-05-04 | |
| 2019-06-30 | 352.10M shares 10-Q · filed 2020-08-06 | 351.70M shares 10-Q · filed 2020-08-06 | 351.77M shares derived: average of 3 quarters · filed 2021-05-04 | 351.70M shares derived: average of 4 quarters · filed 2021-05-04 | |
| 2019-03-31 | 351.30M shares 10-Q · filed 2020-05-07 | 351.60M shares derived: average of 2 quarters · filed 2021-05-04 | 351.57M shares derived: average of 3 quarters · filed 2021-05-04 | 351.50M shares derived: average of 4 quarters · filed 2021-05-04 | |
| 2018-12-31 | 351.90M shares derived: 8-K 12 month − 10-Q 9 month · filed 2021-05-04 | 351.70M shares derived: average of 2 quarters · filed 2021-05-04 | 351.57M shares derived: average of 3 quarters · filed 2021-05-04 | 351.30M shares 8-K · filed 2021-05-04 | |
| 2018-09-30 | 351.50M shares 10-Q · filed 2019-11-04 | 351.40M shares derived: average of 2 quarters · filed 2019-11-04 | 351.10M shares 10-Q · filed 2019-11-04 | ||
| 2018-06-30 | 351.30M shares 10-Q · filed 2019-08-06 | 351.00M shares 10-Q · filed 2019-08-06 | |||
| 2014-03-31 | 334.90M shares 10-Q · filed 2014-05-09 | ||||
| 2013-03-31 | 305.80M shares 10-Q · filed 2014-05-09 | 305.76M shares 10-Q · filed 2013-05-03 | |||
| 2012-03-31 | 307.78M shares 10-Q · filed 2013-05-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |